Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Mandate On Rx Firms Would Protect Reimportation Under Senate Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

The legislation requires drug manufacturers to notify FDA of any manufacturing changes that might circumvent reimportation. Bill sponsors include Dorgan, Kennedy and McCain.

You may also be interested in...



Health Committee Hearings To Focus On HHS Importation Report

The committee will also hold hearings on the Dorgan/Snowe importation bill by the end of April. The legislation, which differs from legislation introduced by the senators last year, is backed by Finance Committee Chairman Grassley.

Health Committee Hearings To Focus On HHS Importation Report

The committee will also hold hearings on the Dorgan/Snowe importation bill by the end of April. The legislation, which differs from legislation introduced by the senators last year, is backed by Finance Committee Chairman Grassley.

Four Senate Bills Signal Start Of 2005 Rx Importation Debate

Two partisan bills will compete with the reintroduction of the Dorgan/Snowe bill and the Pharmaceutical Market Access Act passed by the House in 2003. The Senate Health Committee plans to hold a hearing on the Dorgan/Snowe bill within 90 days.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel